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C3 glomerulopathy (C3G) is an umbrella classification for severe renal diseases
characterized by predominant staining for complement component C3 in the
glomeruli. The disease is caused by a dysregulation of the alternative pathway
(AP) of the complement system. In more than half of C3G patients C3 nephritic
factors (C3NeFs) are found. These autoantibodies bind to the AP C3 convertase,
prolonging its activity. C3NeFs can be dependent or independent of the complement
regulator properdin for their convertase-stabilizing function. However, studies to
determine the properdin-dependency of C3NeFs are rare and not part of routine
patient workup. Until recently, only supportive treatments for C3G were available.
Complement-directed therapies are now being investigated. We hypothesized that
patients with properdin-dependent C3NeFs may benefit from properdin-inhibiting
therapy to normalize convertase activity. Therefore, in this study we validated two
methods to distinguish between properdin-dependent and properdin-independent
C3NeFs. These methods are hemolytic assays for measuring convertase activity
and stability in absence of properdin. The first assay assesses convertase
stabilization by patient immunoglobulins in properdin-depleted serum. The second
assay measures convertase stabilization directly in patient serum supplemented with
the properdin-blocking agent Salp20. Blood samples from 13 C3NeF-positive C3G
patients were tested. Three patients were found to have properdin-dependent C3NeFs,
whereas the C3NeF activity of the other ten patients was independent of properdin. The
convertase-stabilizing activity in the samples of the patients with properdin-dependent
C3NeFs disappeared in absence of properdin. These data indicate that inhibition
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of properdin in patients with properdin-dependent C3NeFs can normalize convertase
activity and could represent a novel therapy for normalizing AP hyperactivity. Our assays
provide a tool for identifying C3G patients who may benefit from properdin-inhibiting
therapy and can be incorporated into standard C3G laboratory investigations.
Keywords: complement system, alternative pathway, convertase, properdin, C3 nephritic factor, C3
glomerulopathy, therapy, Salp20
INTRODUCTION
C3 glomerulopathy (C3G) is a recently introduced classification
for rare but severe renal diseases characterized by predominant
deposition of complement component C3 in glomeruli (1, 2).
C3G patients may present with a variety of symptoms, including
glomerulonephritis with varying degrees of renal failure,
hematuria, hypertension, proteinuria, nephrotic syndrome, and
low serum C3. Prognosis is generally poor with a high risk of
progression to end-stage renal diseases and a risk of recurrence
in kidney transplants of∼50% (3–10). Diagnosis of C3G is made
when on kidney biopsy immunofluorescence staining for C3
is ≥2 orders of magnitude higher than for immunoglobulins
(Igs) (2, 11, 12). Based on electron microscopy appearance,
C3G can be subdivided into dense deposit disease (DDD) and
C3 glomerulonephritis (C3GN). DDD is characterized by very
dense band-like intramembranous deposits, whereas the deposits
found in C3GN are less dense and can show a more variable
pattern (2, 12).
The complement system is part of innate immunity and
clears pathogens and aberrant host cells from the body (13,
14). Complement can be activated via three pathways: the
classical, lectin, and alternative pathway (AP). The complement
depositions in C3G are the result of uncontrolled AP activity (12,
15). The AP is constantly active at a low rate by the spontaneous
hydrolysis of C3 (tick-over), which allows a quick response to
triggers. Hydrolyzed C3 [C3(H2O)] is functionally similar to C3b
and able to form an initial C3 convertase after it reacts with Factor
B and Factor D. The resulting C3(H2O)Bb complex cleaves small
amounts of C3 into C3a and C3b. Once the system is triggered,
an amplification loop leads to full activation of the complement
cascade. C3b binds to cell surfaces with its reactive thioester to
promote their phagocytosis in a process known as opsonization.
Besides, bound C3b can form new C3 convertases (C3bBb) that
in turn convert more C3 into C3b. When the C3b density on
a surface becomes high enough, C3bBbC3b complexes, better
known as C5 convertases, can be formed (16). C5 convertases
cleave C5 into its active fragments C5a and C5b, and hereby
Abbreviations: AP, Alternative pathway; C3G, C3 glomerulopathy; C3GN, C3
glomerulonephritis; C3NeF(s), C3 nephritic factor(s); DDD, Dense deposit
disease; EDTA, Ethylenediamine-tetraacetic acid; ELISA, Enzyme-linked
immunosorbent assay; hi-NHS, Heat-inactivated pooled normal human serum;
Ig(s), Immunoglobulin(s); FH, Factor H; FI, Factor I; IC-MPGN, Immune
complex-mediated membranoproliferative glomerulonephritis; Mg-EGTA,
Magnesium-ethylene glycol tetraacetic acid; NHP, Pooled normal human EDTA-
plasma; NHS, Pooled normal human serum; RbE, Rabbit erythrocyte; tmax, (time
point of) maximal convertase activity; 1P-NHS, Properdin-depleted normal
human serum;1C3-NHS, C3-depleted normal human serum.
initiate terminal pathway activity. The end product is a pore-
forming, lytic C5b-9 complex, also known as the membrane
attack complex.
In healthy individuals, the AP is strictly regulated. Circulating
factors in blood, such as Factor H (FH) and Factor I (FI), and
membrane-bound inhibitory proteins act together to protect
from excessive AP activation and AP attack on healthy cells.
Inhibitors of C3 convertase activity promote the decay of
the convertase complex or act as cofactors for FI, which
enzymatically inactivates C3b resulting in C3b breakdown
fragments (14, 17). It is these C3 breakdown fragments that are
typically found in the glomeruli of C3G patients (18). There is
also a positive regulator that promotes instead of inhibits C3
convertase activity: properdin, a glycoprotein mainly synthesized
by leukocytes (19, 20). Properdin stabilizes the C3bBb complex by
forming C3bBbP, which enhances its half-life 5–10 fold (21). The
exact function of properdin in the C5 convertase is not known
yet (20).
When the sophisticated balance of complement activation
and inhibition is disturbed, damage can occur to healthy host
tissues. The glomeruli are thought to be especially vulnerable to
overactive complement activity (22, 23). In patients with C3G,
several pathogenic causes leading to an overactive AP can be
found. Around 20% of patients has mutations in genes encoding
for complement inhibitory proteins (loss-of-function mutations)
or activating components (gain-of-function mutations) (5, 8, 15).
A more common finding in C3G patients are C3 nephritic factors
(C3NeFs). These autoantibodies stabilize the C3 convertase
complex and prolong its activity (24). In contrast to properdin,
C3NeFs are not part of normal human complement homeostasis.
They are found in ∼40–50% of C3GN patients and in ∼80% of
DDD patients (5, 8, 25–27).
C3NeFs are functionally heterogeneous. The autoantibodies
bind to neoepitopes on the C3bBb(P) complex to inhibit the
intrinsic, spontaneous and extrinsic, accelerated decay mediated
by complement regulators to varying degrees (28–32). Besides,
studies dating back to the late 80s/90s have reported that
C3NeFs may be dependent or independent of properdin for
their ability to stabilize convertases (33, 34). Several recent
studies have confirmed the presence of these two types of
C3NeF (4, 27, 31).
At the moment, therapy for C3G is mainly supportive and
entails anti-proteinuric and immunosuppressive medication (10,
12). In recent times, the focus has shifted more and more
toward targeting of the complement system (35). Eculizumab,
a humanized anti-C5 antibody, was proven very efficacious in
patients with atypical hemolytic uremic syndrome (36), which
is also a renal disease strongly associated with uncontrolled AP
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activity. Nonetheless, C3G patients have shown an inconsistent
response to this drug (37). Since the clinical features of C3G
may derive predominantly from C3 activation, C3G patients
may benefit from blocking C3 and/or C3 convertase activity
(38). Therefore, there is increasing interest in inhibition of AP
complement activation at an early phase, such as inhibiting C3,
Factor B or Factor D (35, 39), or non-canonical targets such as
renin, which also has recently been shown to have C3-cleaving
capacities (40).
We hypothesized that C3G patients with properdin-
dependent C3NeFs might benefit from therapies targeting
properdin, leading to normalization of C3 convertase activity.
In this study, we established methods to distinguish between
properdin-dependent and properdin-independent C3NeFs
and subsequently investigated whether convertase stabilization
could be normalized by properdin inhibition in patients with
properdin-dependent C3NeFs.
MATERIALS AND METHODS
Human Serum and EDTA-Plasma Samples
Serum and ethylenediamine-tetraacetic acid (EDTA)-
plasma samples were obtained from patients referred to the
Radboudumc and from healthy controls. Exclusion criteria for
healthy controls were fever, bacterial and/or viral infections in
the preceding 2 weeks, chronic illness, inherited or acquired
immune disorders, and immunosuppressive medication. The
study was carried out in accordance with the recommendations
of the appropriate version of the Declaration of Helsinki. Samples
were processed according to protocol as previously described
(41). For control material, pooled normal human serum
(NHS) and pooled normal human EDTA-plasma (NHP) were
produced from samples of 20 healthy volunteers. In addition,
heat-inactivated NHS (hi-NHS) was prepared by incubating
NHS for 30min. at 56◦C. Properdin-depleted (1P-NHS; A339)
and C3-depleted normal human serum (1C3-NHS; A314) were
purchased from Complement Technology (Tyler, TX, USA).
Quantification of Complement Proteins
and Activation Products
Serum C3 levels were measured by nephelometry following the
standardized diagnostic procedure of the Radboudumc using
IMMAGE R© Immunochemistry Systems (Beckman Coulter,
Brea, CA, USA). Sandwich enzyme-linked immune sorbent
assays (ELISAs) were used to quantify all other complement
(regulatory) proteins. Except for the properdin ELISA, all
protocols are currently operational in routine diagnostics at
the Radboudumc. C5 levels were measured in human serum
or EDTA-plasma using goat polyclonal antiserum to human
C5 (A306; Quidel, San Diego, CA, USA), combined with a
mouse monoclonal anti-human C5 antibody (A217; Quidel) for
detection. FH and FI were quantified in serum or EDTA-plasma
samples. FH was detected using a polyclonal goat anti-human FH
antibody (A312; Quidel), followed by a mouse monoclonal anti-
human FH antibody (A229; Quidel). FI was quantified using a
polyclonal sheep anti-human FI antibody (LN1301932; LabNed,
Amstelveen, the Netherlands) and subsequently detected using
a mouse monoclonal anti-human FI antibody (OX-21; ProSci,
Poway, CA, USA). Plate readout was similar for these assays,
namely using polyclonal goat anti-mouse antibodies conjugated
to horseradish peroxidase (P0447; Dako, Glostrup, Denmark)
followed by the substrate o-phenylenediamine dihydrochloride.
Results were calculated based on calibration lines produced by
the commercially obtained purified human protein standards C5
(204888; Calbiochem), FH (341274; Calbiochem), and FI (A138,
Complement Technology). The activation markers C3bBbP,
C3bc, and C5b-9 were measured in EDTA-plasma by ELISA
as previously described (42, 43). The ELISA for properdin
detection in serum was set up and optimized based on previously
described protocol (44). In brief, a mouse monoclonal anti-
human properdin antibody (A233; Quidel) was used as the
capture antibody and for detection a polyclonal rabbit anti-
human properdin antibody labeled with digoxigenin (a kind
gift of Prof. C. van Kooten, Leiden University Medical Center).
After addition of an anti-digoxigenin antibody conjugated
to horseradish peroxidase (Roche, Mannheim, Germany), the
plate was developed with tetramethylbenzidine and results
were calculated based on a calibration line produced by an
NHS standard that was calibrated against the described serum
standard (44).
Salp20 Production and Purification
ADNA fragment encoding Ixodes scapularis Salp20 [UniProtKB:
Q95WZ1 (residue 22–183)] was amplified by PCR from Salp20
synthetic DNA optimized for mammalian expression (GeneART
ThermoFisher), and ligated into BamHI-NotI sites of vector
pUPE106.03 (U-Protein Express BV, Utrecht, the Netherlands).
The expressed protein contained a cystatin secretion signal
peptide, an N-terminal (His6)GlySer-tag and an C-terminal Ala3
cloning artifact due to the NotI restriction site. The construct
was transiently expressed in N-acetylglucosaminyltranferase I-
deficient (GnTI-) Epstein-Barr virus nuclear antigen I(EBNA1)-
expressing HEK293 cells cultured in suspension (U-Protein
Express BV, Utrecht, the Netherlands). Secreted Salp20 was
captured by incubating culture medium with Ni-Sepharose excel
beads (GE Healthcare) at 4◦C for 2 h, followed by washing with
25mM HEPES pH 7.8, 500mM NaCl, 15mM imidazole. After
elution using the washing buffer supplemented with 250mM
imidazole the sample was further purified by gel-filtration using
a Superdex 200 increase 10/300 GL column (GE Healthcare)
equilibrated in 25mMHEPES pH 7.8, 150mMNaCl. Salp20 was
concentrated to 8.4 mg/ml by centrifugation using a 5-kDa cut-
off concentrator before plunge freezing in liquid nitrogen and
storage at−80◦C.
Ig Purification
Purified Ig fractions were obtained from the EDTA-plasma
samples of patients P1 to P6 and from NHP as previously
described (41). In short, Igs were isolated using a protein
A/G affinity chromatography column (Thermo Fisher Scientific,
Waltham, MA, USA). Ig fractions were subsequently dialyzed
against phosphate buffered saline and concentrated to the
original plasma sample volume using a concentrator with a
10 kDa molecular weight cut-off. The Ig concentrations were
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measured using NanoDrop Spectrophotometer (Thermo Fisher
Scientific) and yielded: 4.7 mg/ml (P1), 2.1 mg/ml (P2), 9.7
mg/ml (P3), 10.2 mg/ml (P4), 8.6 mg/ml (P5), 12.5 mg/ml (P6),
and 10.7 mg/ml (NHP). The Ig fractions were not contaminated
with properdin as tested in the ELISA above.
Convertase Activity Assays
AP convertase activity assays are two-step hemolytic assays in
which the assembly of convertases is separated from C5b-9
formation and hemolysis using a C5-blocking agent. These assays
were performed according to a previously described protocol (41)
but with adaptations in the first step of the assay for convertase
assembly. Rabbit erythrocyte (RbE) working suspensions were
prepared by washing the RbE in a magnesium-ethylene glycol
tetraacetic acid (Mg-EGTA) buffer (2.03mM veronal buffer, pH
7.4, 10mM EGTA, 7mM MgCl2, 0.083% gelatin, 115mM D-
glucose, and 60mMNaCl) followed by calibration to standardize
the number of erythrocytes in each experiment. In all assays,
10 µl of prepared RbE were mixed with 20 µl of 150 nM of
the C5 inhibitor eculizumab diluted in Mg-EGTA. Subsequently,
at different time points 20 µl of human test serum, i.e., NHS,
1P-NHS, patient serum or 1C3-NHS, diluted in Mg-EGTA to
a concentration of 9.5 or 12.5%, was added for the convertase
assembly at 37◦C. Alternatively, the test serumwas supplemented
with Ig fractions in a 1:1 (standard) or 1:3 volume ratio, or with
purified properdin (A139, Complement Technology), Salp20,
and/or C3 (A113, Complement Technology) to obtain final
concentrations as indicated in figure legends. These protein
concentrations are corrected for the used serum percentage, i.e.,
indicating the concentration per volume of undiluted serum.
Patient sera were always tested mixed with an equal volume of
NHS to compensate for possible lowC3 levels (41). As amodel for
patient serumwith lowC3,1C3-NHSwas treated similarly. After
convertase assembly in this first step, erythrocytes were washed
with cold EDTA-gelatin veronal buffer (EDTA-GVB; 4.41mM
veronal buffer, 0.1% gelatin, 130mMNaCl, pH 7.4) to wash away
excessive C5-inhibitor and unbound complement components.
The second step of the assay, in which the recovered erythrocytes
were overlaid with guinea pig serum diluted in EDTA-GVB as a
source of C5b-9 components for generating hemolysis, was not
subjected to any changes in this study. Hemolysis levels are given
as percentage of full lysis of erythrocytes in water, and hi-NHS
served as a negative control in all assays.
RESULTS
Patient Characteristics and Complement
Profiles
For this study, 13 pediatric patients (age range 3–17 years)
who were referred to the Radboudumc because of a (suspicion
of) C3G diagnosis were selected based on a positive test for
prolonged convertase activity, i.e., C3NeF activity, in diagnostic
settings (41), and based on the availability of sufficient and
appropriate serum and plasma samples taken in the diagnostic
phase (Table 1). Subdivision into C3GN or DDD was based on
the renal pathology report following the guidelines described in
the consensus report of the first C3G Meeting (2). One patient
did not meet the C3G criteria and was diagnosed with immune
complex-mediated membranoproliferative glomerulonephritis
(IC-MPGN). Genetic complement analysis and the analysis of
complement parameters in serum/plasma were performed in all
patients (Table 1). Complement activation markers and levels
of complement (regulatory) proteins showed strong variations
among patients. All samples taken for these complement
investigations, including the testing for properdin dependency
of C3NeFs, were obtained during the initial diagnostic phase
at presentation (P2, P4, P5, P6, P8, P9, and P11) or during
a later stage of disease in which patient samples remained
positive for C3NeF activity (P1, P3, P7, P10, P12, and P13).
Patients P1, P3, P7, P10, and P13 continued to show signs of
ongoing complement activation, i.e., low serum C3 levels and
elevated complement activation products, despite of normal renal
function. Interestingly, the levels of C3, C5, and properdin of P12
were decreased at initial presentation (combined with elevated
C3bBbP and TCC), but the complement consumption and renal
function normalized after 1 year. Data shown for this patient in
Table 1 belong to this partial remission phase in which C3NeF
activity remained present, since not enough patientmaterial from
acute phase was available. Due to the absence of EDTA-plasma
material from the acute phase of P8, the reported activation
markers C3bBbP, C3bc, and TCC for this patient are from a later
stage of disease in which there was ongoing C3 activation. Patient
P2 developed end-stage renal disease within the first 3 months
after presentation and received hemodialysis.
Two Novel Methods to Distinguish
Between Properdin-Dependent and
Properdin-Independent C3NeFs
We previously validated a hemolytic assay to monitor convertase
activity over time in human serum. This method enabled the
detection of factors causing increased convertase stability such
as C3NeFs in patient serum (41). In this assay, the stage of
convertase formation by test sera (step 1) is separated from
the standardized stage of C5b-9 formation and hemolysis (step
2) by using the C5 inhibitor eculizumab. We assume that all
important events influencing C3 convertase activity are also
reflected in the C5 convertase activity that eventually generates
the readout. In this study, we aimed to modify the existing assay
to distinguish between properdin-dependent and properdin-
independent C3NeFs. For this purpose, two approaches were
designed in which properdin was eliminated during the first
step of convertase assembly and decay in presence of C3NeFs
(Figure 1). The first method assesses the ability of C3NeF-
positive patient Ig fractions to stabilize convertases formed out
of 1P-NHS. In the second assay, properdin is blocked directly
in serum using the properdin-blocking tick protein Salp20 (45)
to assess the ability of the C3NeFs contained in serum to
cause convertase stabilization. Only samples with properdin-
independent C3NeFs test positive in these assays.
We first investigated the effect of absence of properdin in
the convertase activity assay using 1P-NHS. We confirmed
by ELISA that no residual properdin was detectable in this
commercially obtained 1P-NHS. Whereas maximal convertase
Frontiers in Immunology | www.frontiersin.org 4 June 2019 | Volume 10 | Article 1350
M
ic
h
e
ls
e
t
a
l.
D
e
te
c
tio
n
o
f
P
ro
p
e
rd
in
-D
e
p
e
n
d
e
n
t
C
3
N
e
p
h
ritic
F
a
c
to
rs
TABLE 1 | Complement investigations in C3NeF-positive C3G patients.
Patient Gender
(M/F)
Age at time
of first
presentation
(year)
Age at time
of study
(year)
Diagnosis Genetic
aberrations
Properdin-
dependency
of C3NeF
C3 (mg/L)
[700–1500]
C5 (µg/ml)
[42-93]
Properdin
(µg/ml)
[11.0–28.0]
C3bBbP
(CAU)
[<12]
C3bc
(CAU)
[<15]
C5b-9
(CAU)
[<0.5]
Factor H
(µg/ml)
[122–315]
Factor I
(µg/ml)
[22-41]
(A) PATIENTS OF WHICH BOTH THE Ig FRACTIONS AND SERA ARE TESTED FOR PROPERDIN-DEPENDENCY OF C3NeF
P1 F 8 9 C3GN CFHR5 c.542G>C
(p.R181T)
Independent 130 23.3 17.1 23.1 10.4 8.6 400 34
P2 M 6 6 DDD Independent 400 34.7 15.6 6.74 7.3 1.3 328 50
P3 M 6 17 DDD Independent 90 41.4 14.8 21.4 24.9 1.0 259 25
P4 M 15 15 C3GN Dependent 70 20.7 8.2 29.1 22.8 7.8 311 35
P5 M 5 5 DDD Independent 110 61.1 17.3 7.24 16.3 1.9 184 36
P6 F 5 5 C3GN Independent 1190 52.2 13.0 23.7 9.2 0.5 189 41
(B) PATIENTS OF WHICH THE SERA ARE TESTED FOR PROPERDIN-DEPENDENCY OF C3NeF
P7 M 6 11 DDD Independent 100 48.4 31.8 <2 8.7 0.5 264 22
P8 F 7 7 DDD Independent 141 58.5 31.7 12.4 27.1 0.3 252 26
P9 F 16 16 DDD DGKE c.851G>A
(p.G284E)
Independent 252 41.2 22.7 3.2 4.4 0.4 116 21
P10 F 16 17 C3GN C3 c.691A>C
(p.S231R)
Dependent 91 23.1 9.4 55.8 16.3 8.0 210 21
P11 F 13 13 DDD CFHR1/CFHR4
deletion
Independent 194 35.0 21.6 26.5 8.7 4.9 141 20
P12 M 2 3 C3GN Independent 878 65.7 20.9 15.4 6.9 0.4 309 50
P13 M 11 15 IC-MPGN Dependent 60 5.0 11.3 33.1 26.3 3.5 167 20
Complement investigations were performed at the time of study. Reference ranges based on healthy controls are indicated between square brackets, and values outside this range are indicated in bold italic. All patients tested negative
for the presence of autoantibodies against Factor H. Indicated genetic aberrations are heterozygous variations. C3GN, C3 glomerulonephritis; DDD, dense deposit disease; IC-MPGN, immune complex-mediated membranoproliferative
glomerulonephritis; CFHR5, complement factor H-related 5; C3NeF, C3 nephritic factor.
F
ro
n
tie
rs
in
Im
m
u
n
o
lo
g
y
|w
w
w
.fro
n
tie
rsin
.o
rg
5
Ju
n
e
2
0
1
9
|V
o
lu
m
e
1
0
|A
rtic
le
1
3
5
0
Michels et al. Detection of Properdin-Dependent C3 Nephritic Factors
FIGURE 1 | Two approaches to distinguish between properdin-dependent and properdin-independent C3 nephritic factors (C3NeFs). In the first approach, rabbit
erythrocytes (RbE) are incubated with properdin-depleted normal human serum (1P-NHS) substituted with an equal volume of patient immunoglobulins (Igs). In the
second approach, properdin function is eliminated by adding the properdin-blocking tick protein Salp20 to patient serum, that is always mixed 1:1 with pooled normal
human serum (NHS) to compensate for possible low C3 levels. All incubations in the first step take place under C5 inhibition by eculizumab to prevent complement
activation up to the level of the C5b-9 complex formation and subsequent hemolysis. After a washing step, guinea pig serum in presence of EDTA is added in the
second step of the assay as a source of C5b-9 components to read out the activity of preformed convertase complexes of the first step. Hemolysis is measured over
time to form convertase activity profiles. Prolonged convertase activity in absence of properdin indicates increased convertase stabilization by properdin-independent
C3NeFs, whereas normal convertase stability indicates that the C3NeFs are properdin-dependent.
activity (tmax) induced by NHS is generally reached after 10–
15min of incubation, the tmax of 1P-NHS was reached after
30min (Figure 2A). Reconstitution of 1P-NHS with purified
properdin restored the convertase activity dose-dependently. A
normal physiological concentration of 25µg/ml properdin was
able to completely bring back tmax to 15min as in NHS.
Subsequently, we examined the effect of Salp20 on convertase
formation and decay in the convertase activity assay. The
addition of at least 3.13µg/ml Salp20 (170 nM) to NHS resulted
in convertase activity profiles similar to those of 1P-NHS and
were characterized by a delayed tmax of 30min (Figure 2B).
This supports that effective inhibition of properdin in NHS
was possible using Salp20. If the properdin blocker was added
in much higher concentrations, i.e., up to 100 or 200µg/ml
(up to 11µM), a decrease in maximal hemolysis was observed
(Figure 2C). Therefore, 6.25µg/ml (340 nM) was chosen as
the optimal concentration for properdin blockage in serum
in following experiments. Altogether, both approaches showed
consistent differences between the convertase activity profiles of
serum in absence and presence of functional properdin.
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FIGURE 2 | Properdin depletion or blockage in normal human serum results in
delayed maximal convertase activity. (A) Rabbit erythrocytes were incubated
with properdin-depleted normal human serum (1P-NHS) and increasing
concentrations of purified properdin (P). (B,C) Alternatively, erythrocytes were
incubated with pooled normal human serum (NHS) and increasing
concentrations of Salp20. Protein concentrations indicated are corrected for
the used serum percentages of 3.8 (A) and 5.0% (B,C). Error bars indicate
standard deviations of the mean obtained from three independent
experiments. hi-NHS, heat-inactivated NHS.
Detection of Properdin-Dependent C3NeFs
in Patient Ig Fractions
Patients P1 to P6 all showed prolonged convertase activity in
the assay under default conditions with properdin present. We
confirmed that this prolonged activity was caused by convertase-
stabilizing autoantibodies, i.e., C3NeFs, by adding the purified
Ig fractions of the patient samples to NHS (Figure 3). We
subsequently tested the C3NeF activity of patient Igs in 1P-
NHS. Five out of the six tested C3NeF-containing fractions,
namely of P1, P2, P3, P5, and P6, showed significant prolongation
of convertase activity when added to 1P-NHS (Figure 4). In
contrast, the addition of the Igs of P4 to 1P-NHS did not
induce any change in convertase stability and resulted in a profile
similar to 1P-NHS incubated with control Igs (NHP Igs). Thus,
the C3NeF activity observed in P1, P2, P3, P5, and P6 was
independent of properdin, whereas the stabilizing activity of the
C3NeFs of P4 was likely dependent on presence of properdin
during convertase formation.
Detection of Properdin-Dependent C3NeFs
in Patient Serum
As an alternative approach, we aimed to assess the properdin
dependency of C3NeFs directly in patient serum by blocking
properdin with Salp20. Not enough serum was available for
P5, so EDTA-plasma was used. This material was previously
shown to be compatible with the assay (41). The C3NeFs
contained in the serum or plasma of patients P2, P5, and
P6 clearly retained their ability to prolong the convertase
activity in the presence of Salp20 (Figure 5). The convertase
activity profiles obtained from sera of patients P1, P3, and
P4 were more difficult to interpret for prolonged convertase
activity, since hemolysis levels were lower and maximal activity
was reached at later time points compared to NHS treated
with Salp20.
We hypothesized that this could be due to inadequate
compensation for the low serum C3 levels in the samples
under these particular properdin-lacking conditions. Using
1C3-NHS as a substitute for patient serum with very low
C3 we confirmed this hypothesis. Like patient sera, 1C3-
NHS was tested in a 1:1 ratio with NHS, resulting in half
of the normal C3 levels. This compensation is adequate in
conditions in which properdin is present (41). However, in
serum conditions with properdin absent or inhibited by Salp20,
reduced C3 levels by half significantly altered the activity profile
characterized by a tmax reached at 50min (Figure 6A). Such
activity profile does not allow analysis for prolongation of
convertase activity after tmax is reached. The addition of C3 to
reach physiological levels could restore the activity profile and
tmax dose-dependently (Figure 6B).
Thus, samples P1, P3, and P4 were supplemented with 250
and 500µg/ml purified C3 to shift hemolysis peaks to earlier
time points comparable to those of samples with normal C3.
This recovered the experimental time window to assess the
activity profiles and clearly revealed that the C3NeFs of P1 and
P3 still caused convertase stabilization in absence of functional
properdin, whereas those of P4 did not (Figure 5). As a control,
the addition of C3 to P2 and P5 only resulted in a slightly faster
generation of tmax, but it did not alter the prolonged convertase
activity present in these patients (Supplementary Figure 1).
These results obtained with the Salp20 method correspond to
those generated with 1P-NHS and Igs and further support the
properdin-dependency of the C3NeFs of P4.
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FIGURE 3 | C3NeF activity in patient sera and patient immunoglobulins (Igs). Rabbit erythrocytes were incubated with pooled normal human serum (NHS) mixed with
an equal volume of serum of patients P1, P2, P3, P4, and P6 or EDTA-plasma of P5 to a final concentration of 5%. Alternatively, erythrocytes were incubated with
NHS mixed with an equal volume (1:1; P1, P4, P5, and P6) or 3-fold volume (1:3; P2 and P3) of purified Igs derived from patient samples or with control Igs derived
from pooled normal human EDTA-plasma (NHP). Representative data of at least two independent experiments are shown. hi-NHS, heat-inactivated NHS.
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FIGURE 4 | Detection of properdin-dependent and properdin-independent C3NeFs in C3G patients using properdin-depleted normal human serum (1P-NHS) and
patient immunoglobulins (Igs). Rabbit erythrocytes were incubated with 5% 1P-NHS mixed with an equal volume of purified Igs from patients P1, P2, P3, P4, P5, and
P6 or with control Igs derived from pooled normal human EDTA-plasma (NHP). Error bars indicate standard deviations of the mean obtained from three independent
experiments. NHS, pooled normal human serum; hi-NHS, heat-inactivated NHS.
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FIGURE 5 | Detection of properdin-dependent and properdin-independent C3NeFs in C3G patients using patient serum and the properdin inhibitor Salp20. Rabbit
erythrocytes were incubated with pooled normal human serum (NHS) mixed with an equal volume of serum of patients P1, P2, P3, P4, and P6 or EDTA-plasma of P5
to a final concentration of 5% and in presence of 6.25µg/ml Salp20. Additionally, purified C3 was added for the samples of P1, P3, and P4, according to the
concentrations indicated, which are corrected for the used serum percentage. Error bars indicate standard deviations of the mean obtained from three independent
experiments. 1P-NHS, properdin-depleted normal human serum; hi-NHS, heat-inactivated NHS.
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FIGURE 6 | Effect of low serum C3 concentration on the convertase activity
profile of serum treated with Salp20. (A) Rabbit erythrocytes were incubated
with C3-depleted normal human serum (1C3-NHS) mixed with an equal
volume of pooled normal human serum (NHS) in absence or presence of 6.25
µg/ml Salp20. (B) Alternatively, 1C3-NHS samples treated with Salp20 were
supplemented with increasing concentrations of purified C3. Concentrations
indicated are corrected for the used serum percentages of 5.0 (A) and 3.8%
(B). Representative data of at least two independent experiments are shown.
1P-NHS, properdin-depleted normal human serum; hi-NHS, heat-inactivated
NHS.
Properdin Restores the
Convertase-Stabilizing Activity of
Properdin-Dependent C3NeFs in a C3G
Patient
To confirm the properdin-dependency of the C3NeFs of P4,
functional properdin was restored in both assays by either
reconstituting the 1P-NHS with purified properdin or by
titrating Salp20 to lower, ineffective concentrations in the
patient serum. Convertase stabilization by P4 Igs completely
returned upon addition of purified properdin in concentrations
of 6.25µg/ml or higher (Figure 7A). In a similar way, titration
of Salp20 to concentrations below 6.25µg/ml restored the
convertase stabilization by C3NeFs in the serum of P4
(Figure 7B). Availability of functional properdin also resulted
in a shift of tmax to earlier time points, as we previously
observed in Figure 2. Except for this peak shift, properdin
reconstitution in the samples of P1 and P2, containing properdin-
independent C3NeFs, did not affect the convertase stabilization
(Figures 7C,D). In conclusion, these experiments support our
previous findings that the convertase-stabilizing activity by P4
C3NeFs was dependent on properdin.
Screening for Properdin-Dependent
C3NeFs in Patient Sera Using the Salp20
Method
After the validation of our methods to detect properdin-
dependent C3NeFs in six patients, we then applied the method
using Salp20 for C3NeF characterization in seven other patient
sera that we tested positive for C3NeF (Figures 8A,B). We
chose this Salp20 method for the screening as it is less time
consuming (no Ig purification) and it requires less patient
material. Regardless of the C3 levels of these samples, we first
decided to test all samples with Salp20 to block properdin but
without the addition of extra C3 (Figures 8C,D). In 4 out of
7 samples, we observed that tmax was generated at later time
points compared to NHS treated with Salp20, thereby reducing
the time window in which convertase activity could be assessed.
Hence, these samples, belonging to P8, P10, P11, and P13,
were selected for C3 compensation with 250 and 500µg/ml
C3 (Figures 8E–H). This approach enabled a clear and reliable
assessment of the convertase activity profiles under properdin
blockade. The sera of patients P10 and P13 were completely
unable to cause prolonged convertase activity when properdin
was blocked (Figures 8G,H). Thus, the C3NeF activity in P10
and P13 was properdin-dependent, whereas the convertase-
stabilizing activity in the other five patients was detected
independent of properdin.
In total, we analyzed 13 pediatric patients in this study, three
of which carry properdin-dependent C3NeFs.
DISCUSSION
Patients with C3G have a variable disease course and can present
with heterogeneous genetic backgrounds and complement
activation profiles. This complicates therapeutic choices. The
careful characterization of different types of C3NeF, such as
properdin-dependent and properdin-independent C3NeFs, may
enable a better understanding of the underlying complement
problems and provide better patient stratification. More
importantly, it might lead to new therapeutic options for
C3G patients. This also holds true for patients diagnosed
with IC-MPGN, in which C3NeFs are also common (5). We
hypothesized that inhibiting properdin can compensate for the
convertase-stabilizing effect of properdin-dependent C3NeFs.
In this study, we optimized two simple and reliable methods
to distinguish between properdin-dependent and properdin-
independent C3NeFs. Of the 12 C3G patients and 1 IC-MPGN
patient we tested, 3 patients were found positive for having
properdin-dependent C3NeFs. For these patients, we showed in
vitro proof-of-concept that properdin inhibition in serum could
normalize the convertase activity.
The described assays assess the ability of C3NeFs to stabilize
convertases formed out of serum in which properdin is
eliminated using 1P-NHS or the properdin-inhibiting protein
Salp20 (Figure 1). Hereby, they allow the strict distinction
between C3NeFs that do or do not function in absence of
properdin in a serum environment. Our approaches resemble
those initially developed in the late 80s/90s: they are based on
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FIGURE 7 | Convertase-stabilizing activity of properdin-dependent but not properdin-independent C3NeFs is restored in presence of functional properdin. Patient
immunoglobulins (Igs) of P4 (A) and P1 (C) were incubated with properdin-depleted normal human serum (1P-NHS), and were reconstituted with increasing
concentrations of purified properdin (P). Alternatively, Salp20 was titrated into the patient sera of patient P4 (B) and P2 (D), that were tested mixed with an equal
volume of pooled normal human serum (NHS). Protein concentrations indicated are corrected for the used serum percentage of 5%. Representative data of at least
two independent experiments are shown. hi-NHS, heat-inactivated NHS.
removing properdin from the default assay conditions (33, 34).
In contrast, most of the recently published studies determined
the properdin-dependency of C3NeFs by adding properdin to
the default conditions (4, 27, 31). These studies showed that
some C3NeFs could not be detected when the stabilization
of the C3bBb complex was assessed but could be detected
when C3bBbP stabilization was investigated (4, 27, 31). The
convertase complexes in these studies were formed using purified
components on the platform of sheep erythrocytes or an ELISA-
plate. The advantage of the assays described in our study is that
convertase formation takes place in a whole serum environment,
which more closely resembles physiological conditions regarding
convertase formation and regulation. Therefore, they are more
likely to reveal physiologically relevant stabilizing factors.
Nonetheless, in the current setting, a standardized serum source
is used as well as a rabbit erythrocyte platform, which is not
comparable to the glomerular structures in terms of surface
binding places for complement regulators and complement
inhibitors expressed. Future research may focus on further assay
optimization using human (glomerular) cells.
The two validated assays presented here have their own
benefits and drawbacks. The assay that tests the capability of
patient Igs to stabilize convertases formed out of 1P-NHS has
the advantage that it directly confirms the autoantibody nature
of the convertase-stabilizing factor present in the patient. In
addition, it uses a standardized commercial source for convertase
formation and thereby reduces assay variability. On the other
hand, this approach requires Ig purification which is a relatively
time-consuming step requiring a high volume of patient material.
The second assay, in which the properdin dependency is assessed
directly in patient serum mixed with NHS in presence of
Salp20, has the advantage that it resembles the physiological
situation in the patient more closely. Also, there is no need
for Ig purification (making the assay less time consuming) and
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FIGURE 8 | Screening for properdin-dependent C3NeFs in patient sera using the Salp20 method. Convertase activity was assessed in the serum of patients P7–P13
mixed with an equal volume of pooled normal human serum (NHS) to a final percentage of 3.8% (A,B). Convertase activity in absence of properdin was assessed by
adding 6.25µg/ml Salp20 to these samples (C,D). For P8, P10, P11, and P13, convertase activity was also assessed after compensation for C3 by adding 250 and
500µg/ml purified C3 to the samples (E–H). All concentrations indicated have been corrected for the used serum percentage of 3.8%. Representative data of at least
two independent experiments are shown. hi-NHS, heat-inactivated NHS.
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the amount of serum needed is minimal. For this reason, we
chose this method to screen for other properdin-dependent
C3NeFs in additional patient sera. However, we found that for
some serum samples with very low C3 levels and late onset
of tmax, compensation with purified C3 was needed to create
an experimental time window allowing the reliable assessment
of the convertase activity profiles (Figures 5, 8). This indicates
that experimental conditions should be well-optimized and well-
regulated. Both assays can be easily incorporated in routine
laboratories with expertise in complement methods to be used
for patient screening.
Some studies have reported that properdin-dependency of
C3NeFs correlates with complement biomarker profiles in
various patient groups. Properdin-dependent C3NeFs were
associated with C5 convertase dysregulation and activation of
the terminal pathway, whereas properdin-independent C3NeFs
were predominantly associated with C3 convertase dysregulation
(4, 33, 34). In our study with a small number of patients, we did
not observe such correlations. Decreased C3 and C5 levels and
increased C5b-9 levels were observed with both types of C3NeF
(Table 1). Future research with larger patient numbers may shed
light on the mechanism of action of different circulating C3NeF
types and the association with complement (activation) markers.
During assay development, we gained important insights
in the dynamic process of convertase assembly and decay in
presence or absence of properdin. Using the convertase activity
assays, we showed that in absence of properdin, convertase
readout was obtained after a much longer incubation time
(Figure 2). These results indicate that in absence of this
convertase-stabilizing protein, convertase formation was less
efficient. The process could be easily restored upon addition
of purified properdin in a dose-dependent manner. Thus, our
assay can be used as a platform for future experiments to study
properdin functionality.
In addition, using the Salp20 method we observed that
convertase assembly, especially in absence of properdin,
depended on C3 levels (Figure 6). Addition of purified C3 to
serum samples with low C3 levels could shift the delayed tmax to
earlier time points and restore the ability to analyse the samples
for convertase stabilization (Figures 5, 6, 8). Interestingly, the
samples of P5, P7, P9, and to a lesser extent P2, also had C3 levels
below the normal range but did not require C3 supplementation.
The potency of serum to support efficient convertase formation
depends not only on C3 concentration but also on other
complement (regulatory) proteins (and possibly C3NeFs), which
may altogether give favorable profiles even in combination with
low C3 in some patients. Nevertheless, in general, the patients
who did require C3 supplementation (P1, P3, P4, P8, P10, P11,
and P13) all have low C3 levels, whereas the only ones with C3
levels within the normal range (P6 and P12) did not require C3
supplementation for analysis.
Previous studies have shown that Salp20 displaces properdin
from the convertase due to the higher affinity of properdin
for Salp20 than for C3b (45, 46). In our hands, Salp20 was
indeed an effective inhibitor of properdin (Figure 2). It has been
shown that Salp20 is highly specific for properdin inhibition
(45, 46). No other functions of Salp20 have been reported,
and we did not encounter any critical side effects of Salp20
in current assay settings. Though, we cannot explain why high
Salp20 concentrations partially inhibited maximal hemolysis
levels (Figure 2C).
Using Salp20 as a model, we here evaluated the potential
of properdin-inhibiting therapy in patients with properdin-
dependent C3NeFs. Salp20 could effectively block properdin
and normalize the prolonged convertase activity caused by
properdin-dependent C3NeFs in P4, P10, and P13 (Figures 5, 6,
8). In patients with properdin-independent C3NeFs, properdin
inhibition did not affect the increased convertase stability. These
results support that properdin inhibition has a therapeutic
potential for patients with properdin-dependent C3NeFs, but not
for patients with properdin-independent C3NeFs. For the latter,
alternative therapeutic strategies are needed, e.g., inhibition at the
level of C3 in other ways.
Blocking properdin seems a relatively safe approach for
humans, since properdin-deficient individuals do not show
a severely compromised immune function, apart from the
increased susceptibility to meningitis for which vaccination is
possible (47, 48). Few studies have described blocking anti-
human properdin antibodies or human properdin-competing
compounds so far, and some were used in in vitro and ex vivo
complement-mediated disease models (49–54). Nevertheless,
therapy directed at blocking properdin must be considered
with care, since studies in mice have shown that inhibition
of properdin might result in unexpected outcomes (20). In
two separate C3G mouse models, it was shown that blocking
properdin exacerbated instead of improved disease outcome
(55, 56). However, these models were not initiated by C3NeF
activity but by absence of functional FH, a cause which only
occurs in rare cases of human C3G. Thus, upon properdin-
inhibition, the initial cause of the overactive complement activity,
namely dysfunctional FH, still remained present. In individuals
in which properdin-dependent C3NeFs are responsible for the
complement overactivity, blockage of properdin tackles the
causing factor (albeit indirectly). Further in vivo experiments
using human-compatible properdin blockers are needed to
investigate the therapeutic potential of properdin inhibition in
C3G patients. Potentially, temporary therapy with a properdin
inhibitormight already be enough to bring patients back to a state
of normal complement homeostasis.
In conclusion, we here demonstrated two simple, time-
effective, and reliable methods to distinguish between properdin-
dependent and properdin-independent C3NeFs. We also showed
that properdin inhibition in patients with properdin-dependent
C3NeFs may be a viable therapeutic strategy to normalize
convertase activity.
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